Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors

Clinical trial NCT04609566 · COMPLETED

Trial details

NCT number: NCT04609566
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Melanoma Non-small Cell Lung Cancer Squamous Cell Carcinoma of the Head and Neck

Start date: 2021-01-26
Primary completion: 2026-02-03
Enrollment: 161

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.